BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu D, Balkin ER, Jia F, Ruthengael VC, Smith CJ, Lewis MR. Targeted antisense radiotherapy and dose fractionation using a (177)Lu-labeled anti-bcl-2 peptide nucleic acid-peptide conjugate. Nucl Med Biol 2015;42:704-10. [PMID: 26081917 DOI: 10.1016/j.nucmedbio.2015.05.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
Number Citing Articles
1 Li J, Zhang L, Li W, Lei C, Cao Y, Wang Y, Wang Z, Pang H. Preparation and SPECT/CT Imaging of 177Lu-Labeled Peptide Nucleic Acid (PNA) Targeting CITED1: Therapeutic Evaluation in Tumor-Bearing Nude Mice. Onco Targets Ther 2020;13:487-96. [PMID: 32021292 DOI: 10.2147/OTT.S238098] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Ebrahim AS, Sabbagh H, Liddane A, Raufi A, Kandouz M, Al-Katib A. Hematologic malignancies: newer strategies to counter the BCL-2 protein. J Cancer Res Clin Oncol 2016;142:2013-22. [PMID: 27043233 DOI: 10.1007/s00432-016-2144-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]